Health

Reuters exclusively reports South Korea offers to produce mRNA vaccines

Reuters reported exclusively that South Korea is in talks with mRNA vaccine makers, including Pfizer and Moderna, to produce COVID-19 shots in the country and is ready to offer the capacity to make up to 1 billion doses immediately. The plan, if agreed, would help ease tight global supply of COVID-19 vaccines, particularly in Asia, and put South Korea a step closer to its ambition to become a major vaccine manufacturing center. According to a Reuters source, local vaccine makers, which have the capacity to produce mRNA vaccines immediately, include Hanmi Pharmaceuticals Co Ltd and Quratis Co Ltd.

Market Impact

Shares in Hanmi rose nearly 7% after the Reuters report, and its top shareholder Hanmi Science jumped 10.3%.



Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Pharmaceuticals & Healthcare
Regions: Asia
Countries: South Korea
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Important Regional Story
Sign up for email updates

Subscribe
Sign up for email updates